OXFORD - Chiroscience Group plc ended months of speculation over what it would do with its chiral services business, agreeing to sell 30 percent of its chiral products and services subsidiary Chirotech Technology Ltd. to conglomerate Ascot Plc for £30 million in cash.

The cash will allow Chiroscience (LSE:CRO; Cambridge, U.K.) both to avoid the equity markets and to in-license products or acquire businesses and technologies to complement its drug discovery efforts in pain, cancer and inflammation.